Essa Pharma executives establish Automatic Securities Disposition Plans

Essa Pharma announced that each of its President and CEO, David Parkinson and its Executive VP and COO, Peter Virsik, have established Automatic Securities Disposition Plans – ASDPs. Under U.S. and Canadian securities laws and the company’s trading policies, insiders of ESSA are subject to limits on their ability to sell shares in the company. The ASDPs address this issue by permitting trades to be made in accordance with pre-arranged instructions given when the Participants are not in possession of any material undisclosed information. Up to 808,333 common shares of ESSA may be sold under the ASDPs implemented by the Participants in the aggregate. The ASDPs are designed to allow for an orderly disposition of each of the Participants’ shares in ESSA at prevailing market prices over the course of the approximately 24 months that the ASDPs are expected to be in place. Sales of the common shares under the ASDPs will commence on January 5, 2024, which is expected to be after the company has filed its Form 10-K with the SEC for FY23. At the time of the establishment of the ASDPs, the Participants were not aware of or in possession of any material non-public information about the company or any securities of the company.